MOLEKULYAR-GENETIK TAHLIL USULLARINI QOʻLLASHNI HISOBGA OLGAN HOLDA DIFFERENSIALLASHGAN QALQONSIMON BEZ SARATONINI TASHXISLASH VA DAVOLASH ALGORITMINI ISHLAB CHIQISH
##article.subject##:
differensiallashgan qalqonsimon bez saratoni, molekulyar-genetik tahlil, prognostik markerlar, personallashtirilgan davolash##article.abstract##
Tadqiqotda BRAF-V600E, RET/PTC, TERT, RAS va PAX8-PPAR-γ mutatsiyalarining uchrash chastotasi va kliniko-morfologik ahamiyati differentsiallashgan qalqonsimon bez saratonli (DQBS) 300 nafar bemorlarda baholandi. Bemorlar 2014–2024-yillarda Respublika ixtisoslashtirilgan onkologiya va radiologiya ilmiy-amaliy tibbiyot markazi Toshkent shahar filialida tekshiruvdan o‘tgan. Barcha bemorlarda Bethesda tizimi bo‘yicha sitologiya, TI-RADS tizimi bo‘yicha UTT-stratifikatsiya va molekulyar tahlillar (PCR, FISH) amalga oshirildi. BRAF-V600E mutatsiyasi asosan papilliar kartsinomada (82,9%) aniqlanib, TNM bo‘yicha noqulay ko‘rsatkichlar bilan bog‘liq bo‘ldi; RET/PTC faqat PTC holatlarida (100%), TERT esa follikulyar turda (46,2%) uchradi; RAS va PAX8-PPAR-γ mutatsiyalari faqat FTC turida kuzatildi. UTT belgilar bilan bog‘liqlik kuchsiz bo‘ldi. Olingan natijalar DQBSda molekulyar-genetik tahlilning prognozni aniqlash va davolashni shaxsiylashtirishdagi ahamiyatini tasdiqlaydi.
Библиографические ссылки
Tillyashaykhov M.N., Ibragimov Sh.N., Janklich S.M. The State of Oncological Care for the Population of the Republic of Uzbekistan in 2019 // “Fan” Publishing House. – 2020. (in Russ).
Califano I, Smulever A, Jerkovich F, Pitoia F. Advances in the management of anaplastic thyroid carcinoma: transforming a life-threatening condition into a potentially treatable disease. Rev Endocr Metab Disord 2023.
Capdevila J, Wirth LJ, Ernst T, Ponce Aix S, Lin CC, Ramlau R, Butler MO, Delord JP, Gelderblom H, Ascierto PA, Fasolo A, Führer D, Hütter-Krönke ML, Forde PM, Wrona A, Santoro A, Sadow PM, Szpakowski S, Wu H, Bostel G, Faris J, Cameron S, Varga A, Taylor M. PD- 1 Blockade in Anaplastic Thyroid Carcinoma. J Clin Oncol 2020; 38: 2620-2627.
Ferrari SM, Elia G, Ragusa F, Ruffilli I, La Motta C, Paparo SR, Patrizio A, Vita R, Benvenga S, Materazzi G, Fallahi P, Antonelli A. Novel treatments for anaplastic thyroid carcinoma. Gland Surg 2020; 9: S28-S42.
Gouda MA, Subbiah V. Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E-Positive Adult and Pediatric Solid Tumors. Am Soc Clin Oncol Educ Book 2023; 43: e404770.
Haddad RI, Bischoff L, Ball D, Bernet V, Blomain E, Busaidy NL, Campbell M, Dickson P, Duh QY, Ehya H, Goldner WS, Guo T, Haymart M, Holt S, Hunt JP, Iagaru A, Kandeel F, Lamonica DM, Mandel S, Markovina S, McIver B, Raeburn CD, Rezaee R, Ridge JA, Roth MY, Scheri RP, Shah JP, Sipos JA, Sippel R, Sturgeon C, Wang TN, Wirth LJ, Wong RJ, Yeh M, Cassara CJ, Darlow S. Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2022; 20: 925-951.
Hwang Y, Yun HJ, Jeong JW, Kim M, Joo S, Lee HK, Chang HS, Kim SM, Fang S. Co-inhibition of glutaminolysis and one-carbon metabolism promotes ROS accumulation leading to enhancement of chemotherapeutic efficacy in anaplastic thyroid cancer. Cell Death Dis 2023; 14: 515.
Jannin A, Escande A, Al Ghuzlan A, Blanchard P, Hartl D, Chevalier B, Deschamps F, Lamartina L, Lacroix L, Dupuy C, Baudin E, Do Cao C, Hadoux J. Anaplastic Thyroid Carcinoma: An Update. Cancers (Basel) 2022; 14.
La Vecchia C., Malvezzi M., Bosetti C., et. al. Thyroid Cancer Mortality and Incidence: A Global Overview. Int. J. Cancer. 2015; 136:2187–2195.
Pellegriti G, Frasca F, Regalbuto C, et. al. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013;2013:965212.
Siegel R.L., Miller K.D., Fuchs H.E., A.Jemal Cancer statistics, 2021 CA Cancer J. Clin., 2021:71(1):7-33.
Siegel R.L., Miller K.D., Jemal A. Cancer Statistics, 2019. CA Cancer J. Clin. 2019;69:7–34.
Turkmen E, Sogutlu F, Erdogan M, Biray Avci C. Evaluation of the anticancer effect of telomerase inhibitor BIBR1532 in anaplastic thyroid cancer in terms of apoptosis, migration and cell cycle. Med Oncol. 2023; 40: 196.
Alkhathami, A. G., Altalbawy, F. M. A., Rizaev, J. A., Jeddoa, Z. M. A., & Jabir, M. S. (2025). An overview of lncRNA GAPLINC's role in human cancer growth and metastasis. Archives of Biochemistry and Biophysics, 110506.
Irgashev, K. N., & Rizaev, J. A. (2025). Optimization of clinical outcomes in the rehabilitation of patients with non-caries dental lesions manifesting as pathological abrasion. Medical Research Journal, 1(1), 146–151.
Shakhanova, S. S., Abdurakhmonov, J. A., & Rakhimov, N. M. (2023). Targeted therapy in the palliative treatment of platinum-resistant recurrent ovarian cancer complicated by ascites. The American Journal of Medical Sciences and Pharmaceutical Research, 5(8), 1.
Rizaev, J. A., Rahimov, N. M., & Shakhanova, S. S. (2023). Prostate cancer morbidity and mortality among men in high-risk areas. Eurasian Medical Research Periodical, 18, 101–104.
